RNAi Expansion Into Common Disease — The single biggest change in this market is the move of siRNA into large, chronic indications. The FDA approved Alnylam's Amvuttra for ATTR cardiomyopathy on 20 March 2025, the first RNAi drug shown to cut cardiovascular death and hospitalisation, and the company's TTR franchise grew 151% that year on total revenue of roughly USD 3 Bn. Novartis' Leqvio brings twice-yearly LDL lowering to primary care, and Arrowhead's Redemplo joined Ionis' Tryngolza in lipid disorders in November 2025. These drugs are dosed every three to six months, so each new patient adds years of recurring revenue. siRNA already earns 30.0% of 2025 category revenue and rises to 31.4% by 2035. In structural terms, RNA medicine is becoming a primary-care therapy class rather than an orphan-drug niche.
RNA Therapeutics Market Size, Share, Trends & Forecast 2026–2035
RNA Therapeutics Market by Modality (mRNA, siRNA, Antisense Oligonucleotides, Self-Amplifying RNA, Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities)), by Application (Infectious Disease Vaccines, Oncology, Rare & Genetic Disease, Cardiometabolic Disease, Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine)), by Delivery Technology (Lipid Nanoparticles, Viral Vectors, Polymer-Based Delivery, Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles)), by End User (Biopharmaceutical Companies, CROs/CDMOs, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
RNA Therapeutics Industry Perspective
The Global RNA Therapeutics market was valued at USD 11,864.3 Mn in 2025 and is projected to reach USD 38,424.6 Mn by 2035, growing at a CAGR of 12.47% during the forecast period 2026–2035, according to Vectomat Insights.
The forecast rests on a mix shift: mRNA's share of revenue slides from 45.9% in 2025 to 37.5% by 2035 as siRNA, antisense and self-amplifying RNA compound faster, with Asia Pacific the fastest-growing region.
RNA Therapeutics Market: Overview
RNA Therapeutics Market encompasses every commercial product whose active ingredient is an RNA molecule: messenger RNA vaccines and protein-replacement medicines, small interfering RNA and antisense drugs that silence disease genes, self-amplifying RNA vaccines that copy themselves inside the cell, and an early tier of tRNA, circular RNA, aptamer and microRNA programmes. The report scope covers product revenue plus the delivery systems sold with them, chiefly lipid nanoparticles, GalNAc conjugates, polymers and viral vectors.
The value chain runs in three tiers. Foundational providers such as Maravai LifeSciences (TriLink CleanCap reagents), Aldevron (plasmid DNA and mRNA) and Lonza and Samsung Biologics (contract manufacturing) supply the raw materials and capacity. Specialist developers, including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals and Gennova Biopharmaceuticals, own the chemistry and the clinical data. The application layer is where large sponsors such as Moderna, BioNTech, Pfizer, Novartis and CSL turn those assets into launched medicines and vaccines.
For procurement and investment teams, the value is concentrating in a narrow band: GalNAc-conjugated siRNA for cardiometabolic disease, LNP-delivered mRNA for oncology, and outsourced manufacturing in Asia. This report tracks 4 segmentation dimensions and 35+ countries so buyers can see where share is moving rather than where it sat in 2025.
According to World Health Organization / International Agency for Research on Cancer (IARC), 2024-02-01, About 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide in 2022, and new cases are projected to rise 77% by 2050, the patient pool behind mRNA cancer vaccine development.

Key Insights
- The global RNA therapeutics market grows from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn by 2035, a 12.47% CAGR across the 2026–2035 forecast horizon.
- mRNA is the dominant modality at 45.9% of 2025 revenue (USD 5,440.4 Mn), carried by Comirnaty, Spikevax and the newer mNEXSPIKE and mRESVIA vaccines.
- Self-amplifying RNA is the fastest-growing modality at an 18.6% CAGR, lifting from USD 830.5 Mn in 2025 to USD 4,574.0 Mn by 2035 after Kostaive's EU approval in February 2025.
- Infectious disease vaccines lead applications at 37.9% of 2025 revenue (USD 4,490.9 Mn), though the segment dipped from USD 4,794.9 Mn in 2024 as US COVID-19 demand fell.
- Biopharmaceutical companies account for 60.0% of 2025 spend because sponsors keep RNA synthesis and LNP formulation in-house, while CROs/CDMOs grow fastest at 18.99% a year.
- North America holds 39.0% of global revenue (USD 4,627.1 Mn), with the United States alone at USD 3,701.7 Mn in 2025.
- Asia Pacific is the fastest-growing region; South Korea, at a 14.7% CAGR, is the fastest-growing highlighted country and reaches about USD 2,151.1 Mn by 2035.
- Consolidation is redrawing the competitive map: Novartis closed its roughly USD 12 Bn purchase of Avidity Biosciences in February 2026 and BioNTech absorbed CureVac in December 2025.
- Cardiometabolic disease is the next volume frontier, growing at 16.96% a year as Leqvio, Tryngolza and Redemplo move RNA drugs from rare disease into common chronic conditions.

RNA Therapeutics Market: Report Scope
| Report Name | RNA Therapeutics Market by Modality (mRNA, siRNA, Antisense Oligonucleotides, Self-Amplifying RNA, Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities)), by Application (Infectious Disease Vaccines, Oncology, Rare & Genetic Disease, Cardiometabolic Disease, Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine)), by Delivery Technology (Lipid Nanoparticles, Viral Vectors, Polymer-Based Delivery, Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles)), by End User (Biopharmaceutical Companies, CROs/CDMOs, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 11,864.3 Mn (2025) |
| Market Forecast in 2035 | USD 38,424.6 Mn (2035) |
| Growth Rate (CAGR) | 12.47% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 96 tables & 72 figures |
| Report Code | VMI-1-1-28152 |
| Report Format | |
| Delivery Format | PDF via email delivery and online download portal |
| Published Date | 7 Nov 2026 |
| Research Methodology | Primary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation) |
| Key Companies Covered | Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Moderna, BioNTech, Pfizer, Biogen, Sarepta Therapeutics, CSL, Gennova Biopharmaceuticals, Samsung Biologics, Maravai LifeSciences, Aldevron, Lonza |
| Segments Covered | Modality, Application, Delivery Technology, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Up to 10% free customization: additional country splits, company profiles or modality-level pipeline tracking |
The VMI Advantage: RNA Therapeutics Market Report
Decision-makers comparing market intelligence reports on RNA Therapeutics will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 4 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 15 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
Key Factors Propelling the RNA Therapeutics Market
Validated Delivery Chemistry — Delivery was the problem that held RNA medicine back for two decades. GalNAc conjugation solved it for the liver, allowing quarterly or twice-yearly subcutaneous injections, while lipid nanoparticles proved themselves across billions of COVID-19 vaccine doses. Both are now off-the-shelf choices for new programmes. The value of that IP is visible in the courts: Moderna agreed a USD 2.25 Bn global settlement with Arbutus and Genevant over LNP patents in March 2026. Delivery routes beyond LNPs, including GalNAc and peptide carriers, grow fastest at 18.9% a year in this report. Next, sponsors want to reach tissues beyond the liver, which is why antibody-oligonucleotide conjugates attracted Novartis to Avidity.
Platform M&A by Big Pharma — Big pharma has decided it's quicker to buy RNA capability than to build it. Novartis agreed in October 2025 to acquire Avidity Biosciences for about USD 12 Bn and completed the deal on 27 February 2026, gaining late-stage antibody-oligonucleotide conjugates for neuromuscular disease. AbbVie agreed in June 2025 to pay up to USD 2.1 Bn for Capstan Therapeutics and its in vivo CAR-T approach using targeted LNP-mRNA. BioNTech closed its takeover of CureVac in December 2025, and Sarepta licensed siRNA programmes from Arrowhead for USD 825 Mn upfront. This capital lets smaller developers fund late-stage trials. The three largest deals in the period alone account for more than USD 14 Bn of committed value.
mRNA Cancer Vaccines Reach Phase 3 — Oncology gives mRNA a growth story beyond respiratory vaccines. In August 2026, the Phase 3 INTerpath-001 trial of intismeran autogene with Keytruda met its recurrence-free and distant-metastasis-free survival endpoints in resected melanoma. That makes it the first individualised neoantigen mRNA vaccine to succeed in a pivotal study. Each dose is designed from a patient's own tumour sequence, so pricing will look more like a cell therapy than a vaccine. Oncology already holds 32.0% of 2025 revenue at USD 3,796.6 Mn. BioNTech is pursuing the same field with its own individualised and off-the-shelf mRNA cancer programmes. The proof point arrived with Merck and Moderna's INTerpath-001 readout.
Acquiring Avidity is a defining move that puts Novartis on course to become a leader in neuromuscular diseases, built on RNA-targeting medicines.
Amvuttra's move into ATTR cardiomyopathy turns our TTR franchise into a category growth story rather than a rare-disease niche.
Key Headwinds Facing the RNA Therapeutics Market
US Policy Shift Against mRNA Vaccines — US federal policy has become the main headwind for mRNA vaccines. On 5 August 2025 HHS wound down mRNA development under BARDA, cancelling 22 projects worth about USD 500 Mn. In September 2025 ACIP moved COVID-19 vaccination to individual, shared clinical decision-making, and Pfizer reported a roughly 25% fall in US COVID-19 vaccine sales in the third quarter. Moderna said in January 2026 it would stop starting new late-stage infectious-disease trials because of the backlash. Infectious disease vaccine revenue dropped from USD 4,794.9 Mn in 2024 to USD 4,490.9 Mn in 2025 as a result. This is a structural repricing of US vaccine demand rather than a one-season dip.
Post-Pandemic Revenue Collapse — The companies that built the mRNA industry are still resizing. Moderna's net product sales fell 42% to USD 1.82 Bn in 2025, it cut R&D spend 31%, and second-quarter 2026 revenue was only about USD 0.1 Bn. BioNTech posted EUR 2.87 Bn of 2025 revenue but a net loss of EUR 1.14 Bn. Lower cash flow means fewer shots on goal in infectious disease and slower investment in new capacity. It also pushes vaccine makers toward oncology and partnerships, where returns arrive later. mRNA's share of category revenue slips from 45.9% to 37.5% by 2035 as a result.
High Prices and Reimbursement Limits — Most siRNA and antisense drugs launched for rare disease at prices above USD 400,000 a year. Moving into common conditions forces a reset, because payers won't fund those prices for millions of cardiovascular patients. Germany's AMNOG benefit assessment and NICE in England already cap launch prices, and US Medicare price negotiation adds pressure on older RNA brands. Biogen's Spinraza shows the risk: sales have slid as oral and gene-therapy rivals arrived, prompting the high-dose label approved in March 2026. The test is whether volume growth outruns price erosion. VMI's base case has average realised price per patient falling through 2035 even as revenue grows at 12.47% a year.
Moderna will not start new late-stage infectious-disease vaccine trials while the policy backlash against vaccines in the United States shrinks the market for them.
Where Is the RNA Therapeutics Market Headed Next?
In Vivo Cell Therapy With mRNA — Engineering immune cells inside the body would remove the cost and logistics of ex vivo CAR-T. AbbVie's agreement to buy Capstan for up to USD 2.1 Bn in June 2025 is the clearest bet on targeted LNP-mRNA for this purpose, starting with autoimmune disease. If it works, the addressable market spans every CAR-T indication plus large autoimmune populations. It would also lift demand for specialist LNP and mRNA manufacturing at CDMOs.
Self-Amplifying RNA Vaccines — Self-amplifying RNA copies itself inside the cell, so a much smaller dose produces a lasting immune response. CSL and Arcturus won European approval for Kostaive in February 2025, and Japan's Meiji Seika added domestic production sites. Lower doses mean more vaccine per batch and lower cost per course, which matters for pandemic stockpiles and low-income markets. Gennova's CEPI-backed Nipah programme shows the approach spreading to outbreak pathogens. Self-amplifying RNA grows from USD 830.5 Mn in 2025 to USD 4,574.0 Mn by 2035.
Outsourced RNA Manufacturing — Most new RNA developers will never build their own plants. That leaves CDMOs to supply plasmid, synthesis, LNP formulation and fill-finish, and their share of spend rises from 26.0% in 2025 to 45.7% by 2035. Samsung Biologics, Lonza and Aldevron are adding capacity, and Aldevron showed the speed possible when it manufactured a personalised CRISPR mRNA therapy for a single infant in May 2025. Personalised cancer vaccines will need similar made-to-order production. Contract manufacturers that win this work early will lock in multi-year supply agreements.
Obesity and Long-Acting Metabolic RNA — Obesity is the largest metabolic market of all, and RNA silencing offers dosing measured in months. Wave Life Sciences reported interim Phase 1 data for WVE-007, an INHBE-targeting siRNA, showing visceral fat loss after a single dose, and its shares more than doubled on the news. Cardiometabolic RNA revenue already grows at 16.96% a year in this report. Pairing silencing drugs with GLP-1 medicines for weight maintenance is the commercial angle to watch.
Operational Hurdles in the RNA Therapeutics Market
Cold Chain and Manufacturing Cost — Many mRNA products must ship frozen, which restricts distribution in Africa, Latin America and rural Asia. LNP formulation and sterile fill-finish need specialised suites that cost far more than small-molecule lines. Lonza and Ethris began work on spray-dried, thermostable mRNA in April 2025 to tackle the problem. Until that work reaches products, logistics cost will cap uptake in the regions with the fastest population growth.
Partnering Exits and Pipeline Resets — Not every RNA programme survives contact with late-stage costs. Hansoh opted out of a USD 1.3 Bn biobucks collaboration with Silence Therapeutics, which then slowed Phase 3 plans for zerlasiran. Sarepta cut about 500 jobs in July 2025 as it pivoted to siRNA. These resets show how capital now flows only to programmes with clean data and a clear launch path.

RNA Therapeutics Market: The AI Advantage
AI is changing how RNA sequences are designed before a single batch is made. Moderna worked with IBM on quantum and classical models that predict mRNA secondary structure, presenting the longest mRNA pattern simulated so far at the APS March Meeting in 2026. Structure prediction matters because folding drives stability, translation and immune response. Gennova, with CEPI funding agreed in March 2025, is using AI-enhanced design for its self-amplifying Nipah vaccine.
For buyers and developers, faster in-silico design shortens the time from target to clinical candidate and lowers the number of failed lots. It also favours companies with large sequence-and-outcome datasets, such as Alnylam and Moderna, over newcomers. Over the forecast horizon, AI-designed sequences should become the default for personalised cancer vaccines, where each patient's construct must be built in weeks.
RNA Therapeutics Market: Segmentation
The Global RNA Therapeutics market is segmented by Modality, Application, Delivery Technology, End User.
By Modality
Self-amplifying RNA is the fastest-moving modality, compounding at 18.6% a year from USD 830.5 Mn in 2025 to USD 4,574.0 Mn by 2035, because one replicating strand produces antigen at a fraction of the dose of conventional mRNA. CSL and Arcturus proved the point when the European Commission approved Kostaive in February 2025. mRNA still dominates at 45.9% of 2025 revenue, or USD 5,440.4 Mn, built on Comirnaty, Spikevax and the deepest LNP fill-finish capacity in the category. siRNA follows at 30.0% (USD 3,559.3 Mn) and is the modality to watch on margin: GalNAc conjugation lets drugs such as Alnylam's Amvuttra reach the liver with a quarterly subcutaneous dose. By 2035, mRNA's share slips to 37.5% while siRNA's edges up to 31.4%.
RNA Therapeutics Market: Revenue Split By Modality (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| mRNA | 5,222.3 | 5,263.1 | 5,440.4 |
| siRNA | 3,110.9 | 3,231.8 | 3,559.3 |
| Antisense Oligonucleotides | 1,005.4 | 1,181.9 | 1,440.9 |
| Self-Amplifying RNA | 545.5 | 720.3 | 830.5 |
| Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities) | 515.4 | 593.1 | 593.2 |

By Application
Cardiometabolic disease is the fastest-growing application at 16.96% a year, rising from USD 840.7 Mn in 2025 to USD 4,028.7 Mn by 2035 as Leqvio, Ionis' Tryngolza and Arrowhead's Redemplo bring twice-yearly or monthly RNA dosing to lipid disorders. Infectious disease vaccines remain the largest application at 37.9% of 2025 revenue (USD 4,490.9 Mn), though the segment fell from USD 4,794.9 Mn in 2024 as US COVID-19 uptake dropped after narrower federal guidance. Oncology holds 32.0% (USD 3,796.6 Mn) and gained real clinical proof in August 2026, when Merck and Moderna's personalised mRNA vaccine intismeran met its Phase 3 endpoint in melanoma. Rare and genetic disease keeps 18.0% but grows slowest among the named indications at 8.69%.
RNA Therapeutics Market: Revenue Split By Application (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Infectious Disease Vaccines | 4,628.3 | 4,794.9 | 4,490.9 |
| Oncology | 3,098.8 | 3,326.9 | 3,796.6 |
| Rare & Genetic Disease | 1,419.7 | 1,612.1 | 2,135.6 |
| Cardiometabolic Disease | 691.6 | 701.1 | 840.7 |
| Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine) | 561.1 | 555.2 | 600.5 |
By Delivery Technology
The 'Others' group, which includes GalNAc conjugates, lipid-polymer hybrids, exosomes and peptide carriers, is the fastest-growing delivery route at 18.9% a year, from USD 1,423.6 Mn in 2025 to USD 8,036.8 Mn by 2035, because GalNAc-siRNA drugs need no nanoparticle at all. Lipid nanoparticles remain dominant at 55.7% of 2025 revenue (USD 6,609.2 Mn): every approved mRNA vaccine relies on them, and the IP around them is valuable enough that Moderna paid USD 2.25 Bn in March 2026 to settle LNP patent claims with Arbutus and Genevant. Polymer-based delivery grows at 14.88%. Viral vectors shrink in share from 20.0% to 12.9% by 2035 as non-viral routes take over RNA payloads.
RNA Therapeutics Market: Revenue Split By Delivery Technology (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Lipid Nanoparticles | 5,915.9 | 6,200.5 | 6,609.2 |
| Viral Vectors | 2,564.1 | 2,582.7 | 2,372.9 |
| Polymer-Based Delivery | 1,117.1 | 1,213.8 | 1,458.6 |
| Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles) | 802.4 | 993.2 | 1,423.6 |
By End User
CROs and CDMOs are the fastest-growing end user at 18.99% a year, expanding from USD 3,084.7 Mn in 2025 to USD 17,552.8 Mn by 2035 and overtaking sponsor spend before the end of the forecast horizon. Mid-sized developers can't justify their own LNP suites, so they buy capacity from Lonza, Samsung Biologics and Aldevron. Biopharmaceutical companies still dominate at 60.0% of 2025 spend (USD 7,118.6 Mn) because Moderna, BioNTech and Alnylam run in-house manufacturing built during the pandemic. That share falls to 39.1% by 2035. Samsung Biologics' February 2026 CEPI agreement for outbreak-ready production shows where the contract work is heading. Academic and research institutes hold 14.0%, growing at 13.38%.
RNA Therapeutics Market: Revenue Split By End User (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Biopharmaceutical Companies | 6,461.3 | 6,618.4 | 7,118.6 |
| CROs/CDMOs | 2,880.0 | 3,060.5 | 3,084.7 |
| Academic & Research Institutes | 1,058.2 | 1,311.3 | 1,661.0 |


RNA Therapeutics Market: Production & Volume Analysis, 2025
Vectomat Insights counts volume in patient doses administered and estimates about 136.0 million RNA medicine doses were given worldwide in 2025. Set against USD 11,864.3 Mn of revenue, that is an average of roughly USD 87 per dose. The volume-value split is extreme. mRNA vaccines supply 88.9% of doses but 45.9% of revenue, while siRNA accounts for just 0.4% of doses and 30.0% of value, implying about USD 6,500 per dose for drugs such as Amvuttra and Leqvio. Self-amplifying RNA adds 10.1% of doses at low prices, so volume and value leaders sit at opposite ends of the modality range.
| Metric | 2025 Volume (patient doses administered) | Share of Units |
|---|---|---|
| Total patient doses administered (2025) | 136 | 100.0% |
| mRNA | 121 | 88.9% |
| siRNA | 1 | 0.4% |
| Antisense Oligonucleotides | 0 | 0.2% |
| Self-Amplifying RNA | 14 | 10.1% |
| Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities) | 1 | 0.4% |
Reference point: Moderna — Opened the Moderna Innovation and Technology Centre at Harwell, UK, able to make up to 100 million mRNA vaccine doses a year under a 10-year UK government partnership (September 2025). Up to 100 million doses per year of capacity.
RNA Therapeutics Market: Competitive Landscape
Competition in RNA therapeutics is splitting along modality lines. In gene silencing, a few specialists hold the validated delivery chemistry: Alnylam's GalNAc-siRNA franchise, Ionis' antisense platform and Arrowhead's TRiM system now compete head to head in lipid disorders. In mRNA, the field is consolidating after the pandemic peak, with BioNTech absorbing CureVac and Moderna settling LNP patent claims for USD 2.25 Bn. Big pharma prefers acquisition to internal discovery, and Novartis' Avidity deal sets the price for platforms. Key players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Moderna, BioNTech, Pfizer, Biogen, Sarepta Therapeutics, CSL, Gennova Biopharmaceuticals, Samsung Biologics, Maravai LifeSciences, Aldevron and Lonza, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | U.S. | GalNAc-conjugated siRNA (Amvuttra, Onpattro, Givlaari, Oxlumo) | Expand the TTR franchise into ATTR cardiomyopathy and scale under its 'Alnylam 2030' plan | Won FDA approval for Amvuttra in ATTR cardiomyopathy in March 2025 |
| Ionis Pharmaceuticals | U.S. | Antisense oligonucleotides for rare and cardiometabolic disease | Shift from royalty income to independent commercial launches | Won FDA approval for Dawnzera (donidalorsen) in hereditary angioedema in August 2025 |
| Arrowhead Pharmaceuticals | U.S. | TRiM-platform siRNA for cardiometabolic and pulmonary disease | First in-house launch backed by large platform licensing deals | Won FDA approval for Redemplo (plozasiran) in familial chylomicronemia syndrome in November 2025 |
| Novartis | Switzerland | siRNA (Leqvio) and antibody-oligonucleotide conjugates ('xRNA') | Build an RNA neuroscience platform through acquisition | Completed its roughly USD 12 Bn acquisition of Avidity Biosciences in February 2026 |
| Moderna | U.S. | mRNA vaccines (Spikevax, mNEXSPIKE, mRESVIA) and individualised cancer vaccines | Cut costs, defend respiratory vaccines and move into oncology with Merck | Reported a positive Phase 3 INTerpath-001 readout for intismeran with Merck in melanoma in August 2026 |
| BioNTech | Germany | mRNA vaccines (Comirnaty with Pfizer) and mRNA oncology | Consolidate German mRNA IP and capacity while pivoting to oncology | Closed its acquisition of CureVac in December 2025 |
| Pfizer | U.S. | mRNA COVID-19 vaccine Comirnaty (with BioNTech) | Diversify away from COVID-19 revenue and defend LNP patent position | Reported in November 2025 that US COVID-19 vaccine sales fell about 25% in Q3 2025 after the CDC narrowed its recommendations |
| Biogen | U.S. | Antisense therapy Spinraza (nusinersen) for spinal muscular atrophy | Defend its SMA franchise with a higher-dose regimen | Won FDA approval for high-dose Spinraza in March 2026 |
| Sarepta Therapeutics | U.S. | Neuromuscular gene therapy moving into siRNA via an Arrowhead licence | Rebuild its pipeline around siRNA programmes licensed from Arrowhead | Announced a pivot to siRNA with about 500 job cuts in July 2025 |
| CSL | Australia | Self-amplifying mRNA COVID-19 vaccine Kostaive (with Arcturus) | Commercialise saRNA vaccines through CSL Seqirus' global vaccine network | Secured European Commission approval for Kostaive in February 2025 |
| Gennova Biopharmaceuticals | India | mRNA and self-amplifying mRNA vaccines | Develop outbreak vaccines with global funders for low-cost markets | Signed a CEPI partnership for an AI-enhanced saRNA Nipah vaccine in March 2025 |
| Samsung Biologics | South Korea | Contract development and manufacturing, including mRNA | Scale CDMO capacity and win pandemic-preparedness reservations | Signed a CEPI collaboration for outbreak-ready vaccine production in February 2026 |
| Maravai LifeSciences | U.S. | mRNA raw materials through TriLink BioTechnologies (CleanCap capping) | License CleanCap widely and sell ready-to-use synthesis kits | Launched TriLink's first mRNA synthesis kit with CleanCap in May 2025 |
| Aldevron | U.S. | Plasmid DNA, mRNA and Cas9 mRNA manufacturing (Danaher) | Offer rapid, made-to-order RNA manufacturing for bespoke therapies | Manufactured the first personalised mRNA-based CRISPR therapy, with IDT, in May 2025 |
| Lonza | Switzerland | Contract manufacturing for mRNA and oligonucleotides | Add formulation technologies that cut cold-chain cost | Started a collaboration with Ethris on spray-dried, thermostable mRNA vaccines in April 2025 |
Three strategic themes stand out. First, platform M&A: Novartis, AbbVie and BioNTech all bought RNA capability between June 2025 and February 2026 rather than building it. Second, label expansion into common disease, which turned Amvuttra into a blockbuster-scale product. Third, outsourcing, where Samsung Biologics, Lonza and Aldevron capture work from sponsors that no longer want to own pandemic-sized plants.

Supply Chain Dynamics in the RNA Therapeutics Market
Raw materials and RNA synthesis — The chain starts with plasmid DNA templates, nucleotides, capping reagents and modified uridine. TriLink's CleanCap reagent sits in most commercial mRNA, and Aldevron supplies the plasmid DNA that templates it. For siRNA and antisense drugs, solid-phase oligonucleotide synthesis and GalNAc ligands are the bottleneck inputs. Supply is concentrated in a handful of US and European specialists, so reagent licences and capacity contracts are negotiated years ahead of launch. Key Players: Maravai LifeSciences, Aldevron, Lonza.
Formulation, delivery and contract manufacturing — Next comes encapsulation in lipid nanoparticles, or conjugation to GalNAc for liver-targeted silencing drugs, followed by sterile fill-finish. This is where most capital sits and where outsourcing is growing fastest. Lonza and Samsung Biologics run multi-product suites, and Lonza's work with Ethris on spray-dried mRNA targets the cold-chain cost that still limits distribution. LNP intellectual property, held by Arbutus and Genevant among others, also shapes who can make what. Key Players: Lonza, Samsung Biologics, Aldevron.
Clinical development, approval and commercial delivery — The final stage turns molecules into labelled products. Sponsors run trials, win approvals and sell through specialty pharmacies for silencing drugs or national tenders for vaccines. Alnylam and Ionis sell directly to specialists, while Moderna, BioNTech and CSL depend on government and payer contracts that changed sharply in the US in 2025. Distribution needs frozen or refrigerated logistics, which favours sponsors with established vaccine networks. Key Players: Alnylam Pharmaceuticals, Moderna, BioNTech, Novartis.
RNA Therapeutics Market: Regional Analysis
North America leads with 39.0% of 2025 revenue because it combines the largest specialty-drug reimbursement pool with the FDA's run of RNA approvals, while Asia Pacific grows fastest as Japan and South Korea fund domestic mRNA capacity and contract manufacturers in the region win outsourced work.
North America RNA Therapeutics Market
North America holds 39.0% of global revenue, or USD 4,627.1 Mn in 2025, and the United States accounts for USD 3,701.7 Mn of that, growing at 11.3% a year to about USD 10,798.2 Mn by 2035. Growth here now comes from silencing drugs rather than vaccines. The FDA approved five RNA medicines in 2025, from Amvuttra's ATTR-CM label in March to Redemplo in November, and Ionis' Tryngolza booked USD 108 Mn in its first full year. The principal challenge is federal vaccine policy: HHS cancelled 22 BARDA mRNA projects worth about USD 500 Mn in August 2025, and ACIP moved COVID-19 shots to individual decision-making in September. What this means structurally is a region whose RNA revenue base is rotating from public-health purchasing to specialty-drug reimbursement.
United States RNA Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 3,701.7 Mn |
| Forecast Value (2035) | USD 10,798.2 Mn |
| CAGR (2026–2035) | 11.3% |

Europe RNA Therapeutics Market
Europe accounts for 27.0% of the market, worth USD 3,203.4 Mn in 2025. Germany leads at USD 897.0 Mn and grows at 10.9% a year to about USD 2,524.1 Mn by 2035, helped by BioNTech's December 2025 takeover of CureVac, which put Germany's two mRNA pioneers under one roof. The UK added Moderna's Harwell plant in September 2025, able to make up to 100 million doses a year, and the European Commission approved the first self-amplifying mRNA vaccine, Kostaive, in February 2025. The main constraint is price. Health-technology assessment under Germany's AMNOG process and NICE in England limits launch prices for siRNA drugs that cost six figures a year in the US. Expect Europe's share to hold steady as local manufacturing offsets slower drug uptake.
Germany RNA Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 897.0 Mn |
| Forecast Value (2035) | USD 2,524.1 Mn |
| CAGR (2026–2035) | 10.9% |

Asia Pacific RNA Therapeutics Market
Asia Pacific is the fastest-growing region, taking 23.0% of 2025 revenue at USD 2,728.8 Mn. South Korea is the standout highlighted country: USD 545.8 Mn in 2025, compounding at 14.7% a year to about USD 2,151.1 Mn by 2035. The KDCA launched its mRNA vaccine development support project at full scale in March 2025, and Samsung Biologics signed a CEPI production agreement in February 2026. Japan approved additional domestic sites for Meiji Seika's Kostaive self-amplifying vaccine in January 2025, while India's Gennova is developing a saRNA Nipah vaccine with CEPI. Price is the drag. Japan's regular drug-price revisions and China's volume-based procurement squeeze realised prices. South Korea's 14.7% CAGR is the highest of any country highlighted in this report.
South Korea RNA Therapeutics Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 545.8 Mn |
| Forecast Value (2035) | USD 2,151.1 Mn |
| CAGR (2026–2035) | 14.7% |

Latin America RNA Therapeutics Market
Latin America holds 5.0% of global revenue, about USD 590.2 Mn in 2025. Brazil is the largest market, and its public research body Fiocruz reported that its own mRNA COVID-19 vaccine was effective in animal testing in May 2025. Argentina is the second pole. The region's challenge is affordability: most siRNA and antisense drugs are imported, and public health systems ration high-cost rare-disease treatments through court-ordered access rather than routine reimbursement. Regional capability is coming through PAHO, which backs H5N1 mRNA vaccine development across the region and reported progress on Sinergium's mRNA platform in Argentina in December 2025.
The Middle East RNA Therapeutics Market
The Middle East represents 3.1% of the market, or USD 362.6 Mn in 2025, with the GCC states and Israel accounting for most spending. Demand is concentrated in imported vaccines and a handful of high-cost rare-disease drugs bought by state health systems. Policy is pushing toward local production. Abu Dhabi's Department of Health partnered with Sanofi on a vaccine innovation centre that includes mRNA research, and Saudi Arabia's PIF-backed Lifera is exploring local drug manufacturing with Pfizer. The principal challenge is scale, because rare-disease patient pools are small and most product is still imported. In structural terms, the region is a buyer market building the first layer of its own supply chain.
Africa RNA Therapeutics Market
Africa accounts for 3.0% of global revenue, about USD 352.2 Mn in 2025, led by South Africa and Egypt. Almost all product is imported, and cold-chain gaps outside major cities still limit how far mRNA vaccines can reach. Local manufacturing is the turning point to watch. The WHO and Medicines Patent Pool's mRNA technology transfer programme, hosted by Afrigen in Cape Town, reached a key milestone in June 2025, and Biovac opened a Cape Town product-development laboratory in November 2025. The EIB and European Commission are providing up to EUR 95 Mn for BioNTech's mRNA site in Kigali, Rwanda. Once those plants supply regional tenders, Africa's share should start to rise from its current low base.


Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
RNA Therapeutics Market: Regulatory and Government Backing
Public research funding and pandemic-preparedness procurement — In August 2025 HHS wound down mRNA vaccine development under BARDA, cancelling 22 projects worth about USD 500 Mn and redirecting funds to other platforms. The decision removes the largest single public buyer of new mRNA vaccine programmes. (BARDA (US HHS) mRNA portfolio)
Technology transfer to low- and middle-income countries — The WHO and Medicines Patent Pool programme, with Afrigen's Cape Town hub, trains manufacturers across Africa, Asia and Latin America to make mRNA vaccines. Partners discussed its Phase 2.0 at the G20 in June 2025. (WHO mRNA Technology Transfer Programme)
National vaccine-sovereignty programmes — South Korea's disease-control agency launched its mRNA vaccine development support project at full scale in March 2025 and selected GC Green Cross as a participant in April. Japan runs a parallel effort through its SCARDA vaccine R&D centre. (KDCA mRNA Vaccine Development Support Project (South Korea))
Public-private manufacturing partnerships — Under a 10-year agreement with the UK government, Moderna opened its Harwell mRNA plant in September 2025 with capacity for up to 100 million doses a year. The EU's HERA EU FAB network follows the same model of reserved surge capacity. (UK–Moderna 10-year strategic partnership)
RNA Therapeutics Market: Latest Industry Moves
Activity over the past 20 months has clustered around two themes, platform acquisitions and RNA drug approvals in common disease, with US vaccine policy pulling in the opposite direction.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Mar 2025 | Alnylam Pharmaceuticals | Regulatory | FDA approved Amvuttra (vutrisiran) for ATTR cardiomyopathy, the first RNAi therapeutic shown to reduce cardiovascular death and hospitalisation. [source] | Opens a large cardiovascular population to siRNA and anchors Alnylam's 2025 revenue growth. |
| Jun 2025 | AbbVie | M&A | AbbVie agreed to acquire Capstan Therapeutics for up to USD 2.1 Bn, gaining an in vivo CAR-T platform built on targeted LNP-mRNA. [source] | Validates mRNA as a route to cell therapy without ex vivo manufacturing. |
| Dec 2025 | BioNTech | M&A | BioNTech closed its acquisition of CureVac, including the subsequent offering period, combining Germany's two leading mRNA developers. [source] | Consolidates European mRNA IP and manufacturing under one owner. |
| Feb 2026 | Novartis | M&A | Novartis completed its roughly USD 12 Bn acquisition of Avidity Biosciences and its antibody-oligonucleotide conjugates for neuromuscular disease. [source] | The largest RNA platform deal of the period sets the valuation benchmark for delivery chemistry. |
| Mar 2026 | Moderna | Other | Moderna agreed a USD 2.25 Bn global settlement of lipid nanoparticle patent litigation with Arbutus Biopharma and Genevant Sciences. [source] | Removes Moderna's main LNP patent overhang and highlights the licensing value of delivery IP. |
| Aug 2026 | Moderna | Other | With Merck, Moderna reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free survival endpoint in resected melanoma. [source] | First Phase 3 success for an individualised mRNA cancer vaccine, opening oncology as an mRNA growth market. |
Research Methodology
Overall approach
Vectomat Insights built the RNA therapeutics model bottom-up from product-level revenue for approved mRNA, siRNA, antisense and self-amplifying RNA medicines, then cross-checked it top-down against company-reported RNA revenue and national pharmaceutical spending. Pipeline products were added from their expected launch year using probability-of-approval weights by phase and modality.
Primary research
Analysts interviewed business-development, manufacturing and market-access staff at RNA drug developers, LNP and oligonucleotide CDMOs, and raw-material suppliers, along with hospital pharmacists and lipid-clinic specialists. Interviews tested pricing assumptions, dosing frequency, outsourcing rates and the expected effect of US vaccine-policy changes.
Secondary research
Secondary sources included company annual reports and earnings releases (Alnylam, Ionis, Moderna, BioNTech, Pfizer, Novartis), FDA and EMA approval records, HHS and BARDA announcements, WHO and CEPI programme documents, clinical-trial registries and patent litigation filings covering lipid nanoparticle IP.
Data validation
Segment and regional values were reconciled to the USD 11,864.3 Mn 2025 total, country values were checked against their regional totals, and modality revenue was cross-checked against the reported product sales of leading companies. Growth rates were tested for consistency between modality, application, delivery and end-user views.
Market Coverage Definitions
How this report defines the scope of the RNA Therapeutics Market: what each segment and sub-segment includes.
| Segment | Market Coverage Definition |
|---|---|
| By Modality | Segments the market by the RNA-based molecule type used in the therapeutic, covering mRNA, siRNA, antisense oligonucleotides, self-amplifying RNA, and other emerging RNA formats. |
| By Application | Segments the market by the therapeutic or preventive use of the product, covering infectious disease vaccines, oncology, rare and genetic disease, cardiometabolic disease, and other emerging application areas. |
| By Delivery Technology | Segments the market by the platform used to carry RNA molecules into target cells, covering lipid nanoparticles, viral vectors, polymer-based delivery, and other delivery approaches. |
| By End User | Segments the market by the type of organization developing or deploying RNA therapeutics, covering biopharmaceutical companies, CROs and CDMOs, and academic and research institutes. |
By Modality
| Sub-Segment | Market Coverage Definition |
|---|---|
| mRNA | Synthetic messenger RNA encoding a target antigen or therapeutic protein, delivered to cells to direct in-vivo protein production. Covers approved prophylactic vaccines and an expanding pipeline of protein-replacement and cancer vaccine candidates. |
| siRNA | Small interfering RNA that silences expression of a specific disease-causing gene by degrading its messenger RNA before it can be translated into protein. Typically used for chronic conditions where infrequent dosing, often a few times a year, is a clinical advantage. |
| Antisense Oligonucleotides | Short synthetic single-stranded nucleic acid sequences that bind complementary messenger RNA to block, modify, or degrade its translation. Widely used to treat rare and genetic diseases where a single faulty gene drives the condition. |
| Self-Amplifying RNA | A next-generation RNA construct that includes a self-replicating mechanism, allowing lower administered doses to generate an immune or therapeutic response comparable to or stronger than conventional mRNA. |
| Others | Additional and emerging RNA modalities, including circular RNA and RNA aptamers, currently at earlier stages of clinical development relative to the established modalities above. |
By Application
| Sub-Segment | Market Coverage Definition |
|---|---|
| Infectious Disease Vaccines | RNA-based vaccines developed to prevent viral and other infectious diseases, the modality's most commercially established application following large-scale deployment in recent years. |
| Oncology | RNA therapeutics designed to treat cancer, including personalized and off-the-shelf cancer vaccine candidates and RNA-based approaches that silence oncogenic drivers. |
| Rare & Genetic Disease | RNA therapeutics targeting inherited and ultra-rare genetic conditions, an area where antisense oligonucleotide and siRNA modalities have achieved some of the earliest regulatory approvals in the category. |
| Cardiometabolic Disease | RNA therapeutics addressing cardiovascular and metabolic conditions, including elevated triglyceride and lipoprotein levels and related chronic disease risk factors. |
| Others | Additional therapeutic areas under RNA-based investigation, including autoimmune and inflammatory conditions. |
By Delivery Technology
| Sub-Segment | Market Coverage Definition |
|---|---|
| Lipid Nanoparticles | Fat-based particles that encapsulate and protect RNA molecules during delivery into target cells. The dominant delivery platform for approved mRNA products and a growing number of siRNA therapeutics. |
| Viral Vectors | Modified viruses used to carry RNA-based genetic material into target cells. More widely established in gene therapy but applied selectively within RNA therapeutics for specific delivery requirements. |
| Polymer-Based Delivery | Synthetic polymer carriers used as an alternative to lipid nanoparticles for protecting and delivering RNA payloads, an area of active development aimed at diversifying away from lipid-nanoparticle-dependent supply chains. |
| Others | Additional delivery approaches, including conjugate-based delivery systems such as GalNAc conjugates used for liver-targeted siRNA and antisense therapeutics. |
By End User
| Sub-Segment | Market Coverage Definition |
|---|---|
| Biopharmaceutical Companies | Pharmaceutical and biotechnology companies developing and commercializing RNA therapeutics, the primary buyers of RNA synthesis, lipid nanoparticle formulation, and related manufacturing services. |
| CROs/CDMOs | Contract research and development manufacturing organizations providing clinical trial support, process development, and manufacturing capacity to RNA therapeutics developers that do not operate in-house production. |
| Academic & Research Institutes | Universities and research institutions conducting early-stage RNA therapeutics discovery and preclinical research, often in partnership with or licensing technology to biopharmaceutical companies. |
Market Assessment Framework
The four-step framework used to size and validate the RNA Therapeutics market.
- 1
Bottom-Up Approach
Market value is built up from individually identified RNA therapeutics, starting with approved and late-stage pipeline products across mRNA, siRNA, antisense oligonucleotide, and self-amplifying RNA modalities. Revenue for each product is estimated from treated patient or dosed population, price per course or per dose, and reimbursement coverage, then aggregated upward to the modality, application, and total market level.
- 2
Volume-Based Assessment
Dosing volumes are estimated separately for one-time or infrequent therapies, such as siRNA treatments dosed a few times a year, and for higher-frequency products, such as mRNA vaccines administered to large eligible populations during defined campaigns. Eligible population, uptake rate, and dosing frequency are modeled by modality and application rather than applying a single volume assumption across the market.
- 3
Price & Revenue Benchmarking
List prices, net prices after rebates, and per-course costs are benchmarked against publicly disclosed pricing for comparable approved RNA therapeutics in similar indications, adjusted for regional reimbursement differences. Benchmarking distinguishes between orphan and rare-disease pricing, which tends to be substantially higher per patient, and higher-volume applications such as infectious disease vaccines.
- 4
Market Validation & Triangulation
Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported product revenue, clinical trial enrollment and pipeline disclosures, and manufacturing capacity announcements from lipid nanoparticle and oligonucleotide CDMOs. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.
Specialized Analyst Insights
The RNA therapeutics market has moved well beyond the mRNA vaccines that first brought the category to wide public attention. siRNA and antisense oligonucleotide therapies now account for a growing share of approved products and pipeline value, largely because they offer a different clinical proposition: chronic disease management with infrequent dosing, sometimes as little as a few injections a year, rather than the single-dose or short-course model that defined early mRNA vaccine use. Self-amplifying RNA is emerging as a further refinement, aiming to achieve comparable immune responses at lower administered doses.
Delivery technology, not the RNA payload itself, has become one of the clearest bottlenecks and competitive battlegrounds in this market. Lipid nanoparticle formulation remains the dominant platform for both mRNA and a growing number of siRNA products, but the concentration of lipid nanoparticle intellectual property and manufacturing know-how among a relatively small number of specialized developers has pushed companies to invest in alternative delivery approaches, including polymer-based carriers and conjugate systems such as GalNAc, partly to reduce dependency on a narrow supplier base.
Large pharmaceutical companies have increasingly chosen to acquire specialized RNA platform companies rather than build equivalent capability internally, a pattern that reflects how technically demanding RNA drug development remains even as the modality has matured. Deals that bring in circular RNA, in vivo cell engineering, or novel delivery platforms give larger companies faster access to differentiated technology than an internal research program would typically provide, while giving the acquired company's platform a path to larger-scale clinical and commercial execution.
Manufacturing capacity and its geographic distribution have become a strategic concern in their own right, separate from any single product's regulatory progress. Efforts to onshore mRNA drug product manufacturing in the United States sit alongside continued build-out of RNA and lipid nanoparticle manufacturing capacity across Asia, reflecting a broader industry preference for geographically diversified, redundant supply chains over concentrating production in a single region, a lesson drawn in large part from pandemic-era supply constraints.
Regional Regulations
Regulatory authorities and requirements across 9 jurisdictions
| Region | Key Regulatory Authorities / Frameworks | Government Regulations and Regulatory Considerations |
|---|---|---|
| North AmericaU.S. | U.S. FDA | RNA therapeutics, including mRNA vaccines, siRNA, and antisense oligonucleotides, are regulated as biologics and reviewed through the Biologics License Application pathway rather than the small-molecule New Drug Application process used for most conventional medicines. Since dedicated chemistry, manufacturing, and controls guidance specific to RNA therapeutics is still developing, sponsors currently work from FDA guidance adapted from adjacent biologics and gene therapy frameworks, an area regulators and industry groups have flagged for further clarification as the pipeline matures. |
| Europe | European Commission, EMA | RNA therapeutics are reviewed centrally by the EMA, with the Committee for Medicinal Products for Human Use issuing a scientific opinion before the European Commission grants EU-wide marketing authorization. Some RNA-based gene therapies qualify for classification as advanced therapy medicinal products, while most approved siRNA and antisense oligonucleotide products instead move through the standard centralized biologics pathway. |
| Asia PacificJapan | PMDA, MHLW | RNA therapeutics are regulated under Japan's Pharmaceuticals and Medical Devices Act, with PMDA conducting scientific review and MHLW granting final marketing approval. Japan's SAKIGAKE designation system can accelerate review for innovative RNA-based therapies addressing serious unmet medical needs. |
| Asia PacificChina | NMPA | RNA therapeutics are regulated under China's drug registration framework, administered by the NMPA, which has cleared a growing number of domestically developed mRNA and siRNA candidates for clinical trials in recent years. The pace of domestic clinical trial clearances reflects a rapidly expanding home-grown RNA therapeutics pipeline alongside internationally licensed products entering the market. |
| Asia PacificIndia | CDSCO | RNA therapeutics fall under India's evolving framework for biologics and gene therapy products, with the Central Drugs Standard Control Organisation working alongside the Review Committee on Genetic Manipulation and the Department of Biotechnology on dedicated national guidelines for gene and RNA-based therapy development and clinical trials. |
| Asia PacificSouth Korea | MFDS | RNA therapeutics are regulated as biologics under the Ministry of Food and Drug Safety's review framework. South Korea has been positioning itself as a regional manufacturing and clinical development base for RNA-based medicines, building on its existing strength in large-scale biologics manufacturing. |
| Latin AmericaBrazil | ANVISA | RNA therapeutics are regulated by ANVISA under its biologics registration framework, with import and local registration requirements applying to internationally developed products entering the Brazilian market, where patient access has generally followed major approvals already granted in the US and Europe. |
| Middle East | National health product regulatory authorities, GCC frameworks | RNA therapeutics are generally reviewed under national drug regulatory frameworks, with Gulf Cooperation Council member states working toward greater regulatory harmonization to streamline registration of new biologic and RNA-based therapies across the region. |
| Global / International | ISO, WHO | International standards support national regulatory frameworks for RNA therapeutics manufacturing and quality, including general biologics manufacturing standards, while the World Health Organization has supported guidance and technology-transfer initiatives aimed at expanding regional mRNA manufacturing capacity in underserved regions. |
Strategic Activities
7 strategic developments shaping the RNA Therapeutics Market
| Date | Company / Companies | Development Type | Development and Impact on Market |
|---|---|---|---|
| Mar 2025 | BioNTech | Clinical Hold | The FDA placed a clinical hold on BioNTech's BNT165e, an mRNA vaccine candidate in a Phase I/IIa trial aimed at preventing blood-stage malaria infection. The company disclosed that it was complying with the hold and working with the FDA on the agency's requests, a reminder that even well-funded, experienced mRNA developers face the same clinical-stage safety scrutiny as any other investigational biologic. [source] |
| Mar 2025 | Sanofi, Alnylam | Regulatory Approval | The FDA approved Qfitlia (fitusiran), the first siRNA, RNAi-based therapeutic approved for hemophilia A or B, with or without inhibitors. The approval extended RNA interference technology, already established in rare metabolic and amyloidosis indications, into a much larger and more competitive bleeding disorders market. [source] |
| Jun 2025 | Alnylam | Regulatory Approval | The European Commission approved Amvuttra (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy, extending the siRNA therapy's EU approval beyond its original polyneuropathy indication. The expansion reflected the growing pattern of approved RNA therapeutics broadening into related disease presentations rather than staying confined to their original narrow indication. [source] |
| Nov 2025 | Moderna | Capacity Expansion | Moderna announced a $140 million investment to onshore drug product manufacturing at its Technology Center campus in Norwood, Massachusetts, completing an end-to-end domestic mRNA manufacturing network intended to serve both commercial and clinical needs. The project is expected to create hundreds of biomanufacturing jobs, with completion targeted for the first half of 2027. [source] |
| Feb 2026 | Eli Lilly, Orna Therapeutics | Acquisition | Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, gaining Orna's engineered circular RNA platform paired with novel lipid nanoparticles, including a clinical-ready in vivo CAR-T program for B cell-driven autoimmune disease. The deal reflects a broader pattern of large pharmaceutical companies acquiring specialized RNA delivery and engineering platforms rather than building comparable capability in house. [source] |
| May 2026 | Arrowhead Pharmaceuticals | Regulatory Change | Arrowhead Pharmaceuticals received a positive CHMP opinion recommending EU approval of Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome, a siRNA therapy already approved in the US for the same rare lipid disorder. A final European Commission decision was expected to follow in the second quarter of 2026. [source] |
| Jun 2026 | Ionis Pharmaceuticals | Regulatory Approval | The FDA approved an expanded indication for Tryngolza (olezarsen), an antisense oligonucleotide therapy, as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, broadening the drug's use well beyond its original familial chylomicronemia syndrome approval into a substantially larger patient population. [source] |
Related Analysis
Blog · PharmaceuticalsRNA Therapeutics Grow Up: From One Famous Vaccine Platform to a Whole Drug Class
A hemophilia approval, a $2.4 billion circular RNA acquisition, and a quiet US manufacturing build-out all point the same direction: RNA therapeutics are no longer a single pandemic-era technology but a genuinely diversified drug class with its own trade-offs and open questions.
Read the article →Table of Contents: RNA Therapeutics Market Report
13 chapters · 96 tables & 72 figures. Expand a chapter to see its sub-sections.
Introduction
- Market Definition and Scope
- Research Assumptions
- Currency and Pricing Basis
Research Methodology
- Primary Research
- Secondary Research
- Market Size Estimation
- Data Triangulation and Validation
Executive Summary
- Key Findings
- Analyst Recommendations
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Role of AI in RNA Sequence Design
RNA Therapeutics Market, By Modality
- mRNA
- siRNA
- Antisense Oligonucleotides
- Self-Amplifying RNA
- Others
- Production & Volume Analysis, By Modality, 2025 (patient doses)
RNA Therapeutics Market, By Application
- Infectious Disease Vaccines
- Oncology
- Rare & Genetic Disease
- Cardiometabolic Disease
- Others
RNA Therapeutics Market, By Delivery Technology
- Lipid Nanoparticles
- Viral Vectors
- Polymer-Based Delivery
- Others
RNA Therapeutics Market, By End User
- Biopharmaceutical Companies
- CROs/CDMOs
- Academic & Research Institutes
RNA Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Competitive Landscape
- Market Share Analysis, 2025
- Strategic Developments
- Supply Chain Analysis
Company Profiles
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- Arrowhead Pharmaceuticals
- Novartis
- Moderna
- BioNTech
- Pfizer
- Biogen
- Sarepta Therapeutics
- CSL
- Gennova Biopharmaceuticals
- Samsung Biologics
- Maravai LifeSciences
- Aldevron
- Lonza
Government Policy and Regulatory Framework
- United States, European Union and Asia Pacific
Appendix
List of Tables (selected)
- RNA Therapeutics Market Size, 2023–2035 (USD Million)
- RNA Therapeutics Market: Revenue Split By Modality (2023–2025, USD Million)
- RNA Therapeutics Market: Revenue Split By Application (2023–2025, USD Million)
- RNA Therapeutics Market: Revenue Split By Delivery Technology (2023–2025, USD Million)
- RNA Therapeutics Market: Revenue Split By End User (2023–2025, USD Million)
- RNA Therapeutics Market Production & Volume, By Modality, 2025 (patient doses administered)
- RNA Therapeutics Market Size, By Region, 2025 (USD Million)
- North America RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- Europe RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- Asia Pacific RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- Latin America RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- The Middle East RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- Africa RNA Therapeutics Market Size, By Country, 2023–2035 (USD Million)
- United States RNA Therapeutics Market Snapshot, 2025 and 2035
- Germany RNA Therapeutics Market Snapshot, 2025 and 2035
- South Korea RNA Therapeutics Market Snapshot, 2025 and 2035
- Key Companies: HQ, Focus, Strategy and Recent Actions
- Recent Developments in the RNA Therapeutics Market, 2025–2026
List of Figures (selected)
- RNA Therapeutics Market Size, USD Million, 2025–2035
- RNA Therapeutics Market: Drivers, Restraints, Opportunities & Challenges
- RNA Therapeutics Market Share by Region, 2025
- RNA Therapeutics Market — Segmentation Overview
- RNA Therapeutics Market Share, By Modality, 2025 (%)
- RNA Therapeutics Market Share, By End User, 2025 (%)
- RNA Therapeutics Market — Modality Mix by Region
- RNA Therapeutics Market — Competitive Landscape
- RNA Therapeutics Market — At a Glance
- United States RNA Therapeutics Market Size, USD Million
- Germany RNA Therapeutics Market Size, USD Million
- South Korea RNA Therapeutics Market Size, USD Million
You May Also Be Interested In
Oligonucleotide Therapeutics Market
Overlapping siRNA and antisense modalities and the same specialist developers
Advanced Drug Delivery Technologies Market
Lipid nanoparticle and GalNAc delivery systems sit in both value chains
CAR-T Cell Therapy Market
In vivo CAR-T built on targeted LNP-mRNA links the two buyer groups
PublishedCell Line Development Market
Shared CDMO and bioprocess supplier base
PublishedRadiopharmaceuticals Market
Same pharmaceutical buyer personas in oncology and specialty care
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
What is the forecast CAGR of the RNA therapeutics market?
The global market grows at a 12.47% CAGR from 2026 to 2035, rising from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn. Rates differ widely by modality: self-amplifying RNA grows at 18.6%, antisense oligonucleotides at 15.66%, siRNA at 12.99% and mRNA at 10.22%. By end user, CROs and CDMOs grow fastest at 18.99% a year, according to Vectomat Insights.
How is the RNA therapeutics market segmented in this report?
The report segments the market by modality (mRNA, siRNA, antisense oligonucleotides, self-amplifying RNA and others), by application (infectious disease vaccines, oncology, rare and genetic disease, cardiometabolic disease and others), by delivery technology (lipid nanoparticles, viral vectors, polymer-based delivery and others) and by end user. It also covers 6 regions and 35+ countries, analysing the Middle East separately from Africa, according to Vectomat Insights.
Why is siRNA gaining share in RNA therapeutics?
siRNA drugs need only two to four injections a year, and GalNAc conjugation delivers them to the liver without a nanoparticle. That convenience made Alnylam's Amvuttra viable in ATTR cardiomyopathy and lets Leqvio and Redemplo compete in lipid disorders. siRNA holds 30.0% of 2025 revenue, worth USD 3,559.3 Mn, and its share rises to 31.4% by 2035 as these large indications mature, according to Vectomat Insights.
How much does delivery technology matter in RNA therapeutics?
Delivery decides which tissues a drug can reach, so it shapes both pipelines and patent value. Lipid nanoparticles carry 55.7% of 2025 revenue, worth USD 6,609.2 Mn, and Moderna paid USD 2.25 Bn in March 2026 to settle LNP patent claims. GalNAc conjugates, peptides and other carriers grow fastest at 18.9% a year, while viral vectors lose share, according to Vectomat Insights.
Which country is the fastest-growing in the RNA therapeutics market?
Among the countries highlighted in this report, South Korea grows fastest, at a 14.7% CAGR from USD 545.8 Mn in 2025 to about USD 2,151.1 Mn by 2035. Government backing through the KDCA mRNA vaccine programme and contract-manufacturing capacity at Samsung Biologics support that growth. The United States remains the largest single country at USD 3,701.7 Mn in 2025, according to Vectomat Insights.
How does Vectomat Insights build the RNA therapeutics market estimate?
Analysts sized the market bottom-up from product revenue for approved mRNA, siRNA, antisense and self-amplifying RNA medicines, then checked it top-down against company-reported sales and pharmaceutical spending. Pipeline products enter the model at their expected launch year with phase-based approval odds. Segment, regional and country values are reconciled to the 2025 total of USD 11,864.3 Mn, according to Vectomat Insights.
What role do CDMOs play in the RNA therapeutics market?
CROs and CDMOs supply synthesis, LNP formulation and fill-finish for developers that don't own plants. Their share of spend rises from 26.0% in 2025 to 45.7% by 2035, a growth rate of 18.99% a year, as new entrants and personalised cancer vaccines need flexible capacity. Samsung Biologics, Lonza and Aldevron are the main beneficiaries of that shift, according to Vectomat Insights.
Access the Complete RNA Therapeutics Market Report
300+ pages | 96 tables & 72 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI RNA Therapeutics Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.
About this report
Get a free sample of this report
RNA Therapeutics Market